Livforsakringsbolaget Skandia Omsesidigt Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Livforsakringsbolaget Skandia Omsesidigt lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 79.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,137 shares of the medical research company’s stock after selling 19,700 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Edwards Lifesciences were worth $380,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EW. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at about $32,000. Avior Wealth Management LLC lifted its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,000 shares of company stock worth $547,430 over the last ninety days. 1.27% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 0.9 %

EW stock opened at $70.38 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a market capitalization of $41.51 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The business’s 50 day moving average price is $72.47 and its two-hundred day moving average price is $69.55. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EW shares. Piper Sandler decreased their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. The Goldman Sachs Group lifted their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Finally, Truist Financial restated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.